Merck & Company (6MK) Stock Forecast & Price Target

Compare

69 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

6MK Analyst Ratings

Moderate Buy

13 Buy

6 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Merck

& Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

6MK Stock 12 Month Forecast

Average Price Target

€113.72

▲(14.18% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is €113.72 with a high forecast of €129.81 and a low forecast of €94.33. The average price target represents a 14.18% change from the last price of €99.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"63":"€63","130":"€130","79.75":"€79.8","96.5":"€96.5","113.25":"€113.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":129.813147,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€129.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":113.7249709818,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€113.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.33088682,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€94.33</span>\n  </div></div>","useHTML":true}}],"tickPositions":[63,79.75,96.5,113.25,130],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.437,105.46593438461538,107.49486876923076,109.52380315384615,111.55273753846153,113.58167192307691,115.6106063076923,117.63954069230769,119.66847507692307,121.69740946153846,123.72634384615384,125.75527823076922,127.7842126153846,{"y":129.813147,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.437,104.22838238321538,105.01976476643077,105.81114714964615,106.60252953286154,107.39391191607692,108.18529429929231,108.97667668250769,109.76805906572308,110.55944144893846,111.35082383215385,112.14220621536923,112.9335885985846,{"y":113.7249709818,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.437,102.73652975538461,102.03605951076923,101.33558926615385,100.63511902153846,99.93464877692308,99.2341785323077,98.5337082876923,97.83323804307692,97.13276779846154,96.43229755384615,95.73182730923077,95.03135706461539,{"y":94.33088682,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":83.725,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.197,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.089,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.143,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.388,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.611,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.642,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.407,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.404,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.437,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€129.81

Average Price Target€113.72

Lowest Price Target€94.33

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Geoff Meacham

Citi

€103.52→€107.84

Hold

8.27%

Upside

Reiterated

03/20/26

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (NASDAQ: MLTX), Solid Biosciences (NASDAQ: SLDB) and Merck & Company (NYSE: MRK)

Mohit Bansal

Wells Fargo

€129.41

Buy

29.93%

Upside

Reiterated

03/20/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Chemed (NYSE: CHE) and PROCEPT BioRobotics (NASDAQ: PRCT)

Asad Haider

Goldman Sachs

€103.52→€114.74

Buy

15.20%

Upside

Reiterated

03/19/26

Merck’s Emerging HIV Franchise: Undervalued Long-Acting Opportunity in a $25B+ Market Supporting a Buy Rating

Louise Chen

Scotiabank

€117.33

Buy

17.80%

Upside

Reiterated

03/19/26

Scotiabank Sticks to Their Buy Rating for Merck & Company (MRK)

Courtney Breen

Bernstein

€108→€112

Hold

12.45%

Upside

Reiterated

03/18/26

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM) and Merck & Company (NYSE: MRK)

Emily Field

Barclays

€120.78

Buy

21.26%

Upside

Assigned

03/12/26

Barclays Keeps Their Buy Rating on Merck & Company (MRK)

Trung Huynh

RBC Capital

€122.5

Buy

23.00%

Upside

Reiterated

03/10/26

RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)

Chris Schott

J.P. Morgan

€107.84

Buy

8.27%

Upside

Reiterated

03/05/26

J.P. Morgan Sticks to Their Buy Rating for Merck & Company (MRK)

Carter Gould

Cantor Fitzgerald

€103.52

Hold

3.94%

Upside

Reiterated

02/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (NASDAQ: COGT), Aquestive Therapeutics (NASDAQ: AQST) and Merck & Company (NYSE: MRK)

Luisa Hector

Berenberg Bank

€81.96→€99.21

Hold

-0.39%

Downside

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Opus Genetics (NASDAQ: IRD)

Evan Seigerman

BMO Capital

€116.47

Buy

16.93%

Upside

Reiterated

02/20/26

BMO Capital Reaffirms Their Buy Rating on Merck & Company (MRK)

James Shin

Deutsche Bank

€99.21→€129.41

Buy

29.93%

Upside

Upgraded

02/13/26

Merck upgraded to Buy from Hold at Deutsche BankMerck upgraded to Buy from Hold at Deutsche Bank

Jason Gerberry

Bank of America Securities

€113.88

Buy

14.33%

Upside

Reiterated

02/05/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NASDAQ: NERV), Gossamer Bio (NASDAQ: GOSS) and Merck & Company (NYSE: MRK)

Vamil Divan

Guggenheim

€105.25→€120.78

Buy

21.26%

Upside

Reiterated

02/05/26

Guggenheim Sticks to Their Buy Rating for Merck & Company (MRK)

Terence Flynn

Morgan Stanley

€87.13→€94.03

Hold

-5.59%

Downside

Reiterated

02/04/26

Hold Steady on Merck: Solid Keytruda Base but Pipeline Uncertainty Keeps Upside Limited

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Geoff Meacham

Citi

€103.52→€107.84

Hold

8.27%

Upside

Reiterated

03/20/26

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (NASDAQ: MLTX), Solid Biosciences (NASDAQ: SLDB) and Merck & Company (NYSE: MRK)

Mohit Bansal

Wells Fargo

€129.41

Buy

29.93%

Upside

Reiterated

03/20/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Chemed (NYSE: CHE) and PROCEPT BioRobotics (NASDAQ: PRCT)

Asad Haider

Goldman Sachs

€103.52→€114.74

Buy

15.20%

Upside

Reiterated

03/19/26

Merck’s Emerging HIV Franchise: Undervalued Long-Acting Opportunity in a $25B+ Market Supporting a Buy Rating

Louise Chen

Scotiabank

€117.33

Buy

17.80%

Upside

Reiterated

03/19/26

Scotiabank Sticks to Their Buy Rating for Merck & Company (MRK)

Courtney Breen

Bernstein

€108→€112

Hold

12.45%

Upside

Reiterated

03/18/26

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM) and Merck & Company (NYSE: MRK)

Emily Field

Barclays

€120.78

Buy

21.26%

Upside

Assigned

03/12/26

Barclays Keeps Their Buy Rating on Merck & Company (MRK)

Trung Huynh

RBC Capital

€122.5

Buy

23.00%

Upside

Reiterated

03/10/26

RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)

Chris Schott

J.P. Morgan

€107.84

Buy

8.27%

Upside

Reiterated

03/05/26

J.P. Morgan Sticks to Their Buy Rating for Merck & Company (MRK)

Carter Gould

Cantor Fitzgerald

€103.52

Hold

3.94%

Upside

Reiterated

02/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (NASDAQ: COGT), Aquestive Therapeutics (NASDAQ: AQST) and Merck & Company (NYSE: MRK)

Luisa Hector

Berenberg Bank

€81.96→€99.21

Hold

-0.39%

Downside

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Opus Genetics (NASDAQ: IRD)

Evan Seigerman

BMO Capital

€116.47

Buy

16.93%

Upside

Reiterated

02/20/26

BMO Capital Reaffirms Their Buy Rating on Merck & Company (MRK)

James Shin

Deutsche Bank

€99.21→€129.41

Buy

29.93%

Upside

Upgraded

02/13/26

Merck upgraded to Buy from Hold at Deutsche BankMerck upgraded to Buy from Hold at Deutsche Bank

Jason Gerberry

Bank of America Securities

€113.88

Buy

14.33%

Upside

Reiterated

02/05/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NASDAQ: NERV), Gossamer Bio (NASDAQ: GOSS) and Merck & Company (NYSE: MRK)

Vamil Divan

Guggenheim

€105.25→€120.78

Buy

21.26%

Upside

Reiterated

02/05/26

Guggenheim Sticks to Their Buy Rating for Merck & Company (MRK)

Terence Flynn

Morgan Stanley

€87.13→€94.03

Hold

-5.59%

Downside

Reiterated

02/04/26

Hold Steady on Merck: Solid Keytruda Base but Pipeline Uncertainty Keeps Upside Limited

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months

xxx

Success Rate

19/28 ratings generated profit

Average Return

+4.78%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 67.86% of your transactions generating a profit, with an average return of +4.78% per trade.

1 Year

Trung HuynhRBC Capital

Success Rate

8/11 ratings generated profit

Average Return

+17.89%

Copying Trung Huynh's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +17.89% per trade.

2 Years

xxx

Success Rate

19/21 ratings generated profit

Average Return

+23.11%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.48% of your transactions generating a profit, with an average return of +23.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6MK Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 6MK has received 30 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. 6MK average Analyst price target in the past 3 months is 113.72.

Each month's total comprises the sum of three months' worth of ratings.

6MK Financial Forecast

6MK Earnings Forecast

Next quarter’s earnings estimate for 6MK is -€1.30 with a range of -€1.86 to -€0.72. The previous quarter’s EPS was €1.76. 6MK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.

6MK Sales Forecast

Next quarter’s sales forecast for 6MK is €13.72B with a range of €13.04B to €14.28B. The previous quarter’s sales results were €14.09B. 6MK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.

6MK Stock Forecast FAQ

What is DE:6MK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck & Company’s 12-month average price target is 113.72.

What is DE:6MK’s upside potential, based on the analysts’ average price target?

Merck & Company has 14.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Merck & Company a Buy, Sell or Hold?

Merck & Company has a consensus rating of Moderate Buy, which is based on 13 buy ratings, 6 hold ratings and 0 sell ratings.

What is Merck & Company’s share price target?

The average share price target for Merck & Company is 113.72. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €129.81 ,and the lowest forecast is €94.33. The average share price target represents 14.18% Increase from the current price of €99.6.

What do analysts say about Merck & Company?

Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Merck & Company?

To buy shares of DE:6MK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Merck & Company (6MK) Stock Forecast & Price Target

6MK Analyst Ratings

6MK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck & Company

6MK Analyst Recommendation Trends

6MK Financial Forecast

6MK Earnings Forecast

6MK Sales Forecast

6MK Stock Forecast FAQ

Detailed List of Analyst Forecasts